Parasites of red blood cells: Babesia and Mycoplasma (Proceedings)

Article

Protozoal disease (genus: Babesia) of dogs and cats where merozoites (piroplasms) infect RBCs.

BABESIA

Overview

     • Protozoal disease (genus: Babesia) of dogs and cats where merozoites (piroplasms) infect RBCs

     • Degree of illness is usually dependent on the severity and rate of anemia development.

     • Anemia mainly as a result of immune mediated hemolysis but also due to direct piroplasm damage to RBCs.

Etiology/Pathophysiology

     • Infection (by tick transmission, transplacental, blood transfusion, or, in the case of B. gibsoni, by bite wounds presumably by blood from infected dog entering a bite wound.) followed by 2 week incubation period during which piroplasms infect and multiply in RBCs, resulting in RBC damage mainly from immune mediated processes but also direct RBC lysis.

     • In the case of Rhipicephalus sanguineus tick, larvae, adults and nymphs can all transmit infection; ticks need to be attached for several days; in ticks, the parasite reproduces by sexual reproduction; ticks can be infected by eating a blood meal or by transovarial means.

Dogs

     • Large (4 – 7 µm): B. canis distributed worldwide; 3 sub-species based on biologic, genetic and geographic distribution:

           o B. canisvogeli – USA, Africa, Asia, Australia. Transmitted by R. sanguineus ticks, so disease found in southeastern, southern states, and California.

           o B. canis rossi - Africa (most virulent sub-species)

           o B. canis canis – Europe, areas of Asia

           o Small (2 – 5 µm): several genetically distinct sub-species:

           o B. gibsoni – world-wide distribution (especially Asia) including the USA.

           o B. conradae – (California – genetically distinct from B. gibsoni) – infects only dogs and only reported in California.

           o B. microti-like – Spain, but recently reported in a Pit Bull terrier dog from Mississippi (unknown if this is a local case or imported).

           o Theileria annae – (Spanish dog piroplasm). Reported in Spain and Europe.

Cats

     • Small (2 – 5 µm) – B. felis reported in Africa.

Signalment/History

     • History of tick attachment.

     • History of recent dog bite wound may be a risk for B. gibsoni infection.

     • Any age or breed of dog can be infected.

     • Severity of disease – depends on the strain of the organism, and the age and breed of the animal.

     • B. canis infections - more prevalent in Greyhounds (USA).

     • B. gibsoni infections - more prevalent in American Pit Bull, Staffordshire, and Tosa Inu breeds.

Clinical Features - Dogs

     • Peracute, acute, chronic, or asymptomatic (in some carrier animals).

     • Splenectomy and immunosuppression – severely worsens disease (B. canis rossi) or makes it apparent (B. canis in the USA).

     • Immunosuppression – may result in an increase in parasitemia and manifestation of clinical signs in chronically infected dogs (B. canis in the USA).

     • Most severe disease – caused by B. gibsoni in the USA, and B. canis rossi in Africa.

     • B. canis - rarely causes clinical disease in the USA.

Signs include: Lethargy, anorexia, weight loss, fever.

     • Pale mucus membranes, icterus.

     • Splenomegaly, lymphadenopathy, hemoglobinemia/uria.

     • Gastrointestinal signs - Some dogs develop vomiting, diarrhea, dark feces (from increased bilirubin excretion).

     • Cerebral babesiosis - weakness, disorientation, collapse (B. canis rossi in Africa).

     • Renal/urologic disease – results in renal failure (B. canis rossi in Africa).

Differential Diagnosis

     • Immune mediated diseases - hemolytic anemia, ITP, idiopathic, ehrlichiosis, RMSF, neoplasia, haemobartonellosis, cytauxzoonosis, SLE.

     • Non-immune mediated diseases - hemolytic anemia; heartworm caval syndrome, zinc toxicity, splenic torsion, Heinz body anemia, DIC, PK deficiency, PFK deficiency.

     • Causes of jaundice – hepatic or post-hepatic disease (obstruction or rupture of biliary tract).

Diagnostics

CBC

     • Mild to severe (PCV < 10%) regenerative anemia.

     • Peracute – animal may present before a regenerative response has time to occur.

     • Anemia - may not be present in all cases (e.g. carriers: Greyhounds with B. canis in USA)

     • Spherocytes, autoagglutination and positive Coombs test may also be present.

     • Thrombocytopenia - usually moderate to severe, and can occur without anemia.

     • Variable leukocytosis or leukopenia.

Biochemical profile/urinalysis

     • Hyperbilirubinemia/uria – if hemolysis acute and severe (African cases rather than USA).

     • Hyperglobulinemia - common in chronic cases (sometimes the only blood chemistry abnormality in these cases).

     • Mild elevated liver enzymes - due to anemia/hypoxia.

     • Renal failure and metabolic acidosis (B. canis rossi in Africa).

     • Bilirubinuria – common.

     • Hemoglobinuria – detected less commonly in the USA than in Africa.

Other tests

     • Microscopic examination of stained thin or thick blood smears – can provide definitive diagnosis but sensitivity depends on experience of microscopist; modified Wright's stain best for viewing organism; blood from peripheral capillary (ear prick) may improve sensitivity; can not differentiate sub-species using microscopy.

     • B. canis - large piriforms within RBCs but also ring forms.

     • B. gibsoni - smaller and often single forms are found per RBC.

     • Serology – IFA; false negatives in young dogs and in some infections; does not differentiate species and sub-species; use if microscopic examination negative with high clinical suspicion of disease, but if negative, need to confirm with a PCR.

     • PCR - tests for presence of Babesia DNA in a biological sample (usually EDTA anti-coagulated whole blood), and can differentiate sub-species and species; more sensitive than microscopy.

     • A combination of serology and PCR is considered to offer the highest sensitivity.

Therapeutics

     • Anemic patients - transfusion of whole blood or packed RBCs (for loss of RBC mass).

     • Polymerized bovine hemoglobin solution. May be used if fresh blood is not available.

     • Severely affected patients require aggressive fluid therapy for hypovolemic shock from blood loss (usually as a result of thrombocytopenia with bleeding).

Drugs of choice: no drug regimen is 100% effective, so an infected dog is infected for life.

     • Imidocarb diproprionate (Imizol® , Schering-Plough) - preferred therapy; may clear B. canis infections usually but not B. gibsoni (Asia). Certainly decrease morbidity and mortality

     • Diminazine aceturate (not available in US and not FDA approved). Similar efficacy to Imazol®

     • Metronidazole, clindamycin, and doxycycline: - decrease clinical signs but do not clear infection.

     • Azithromycin – give in combination with atovaquone is preferred Tx for B. gibsoni infections.

     • Prednisone - treat immune mediated component of anemia

ERYTHROCYTIC MYCOPLASMAL INFECTIONS

Definition/Overview

     • Red blood cell destruction and anemia caused by parasite attachment to the external surface of RBCs and immune response by the host.

Etiology/Pathophysiology

     • Haemobartonella felis (cats)and Haemobartonella canis (dogs) – classified at rickettsial bacteria.

     • Recently recognized to be mycoplasmal bacteria based on genetic determinations.

     • Proposed new names:-

           o Mycoplasma haemofelis for a large form of H. felis.

           o Mycoplasma haemominutum for the small form of H. felis.

           o Mycoplasma turicensis – found on PCR only, not seen cytologically

           o Mycoplasma haemocanis for H. canis (dogs).

     • The large species of mycoplasmal organisms infecting cats – generally causes more severe disease than small species.

     • Cats – anemia more severe if FeLV infected. Splenectomy does not make disease worse.

     • Dogs – likelihood of severe anemia greatly increased if splenectomized or with pathologic changes in the spleen.

Signalment/History

     • Worldwide distribtution.

     • Most common in adult (dogs and cats).

     • More common in males cats and FIV-infected cats.

     • No sex prevalence in dogs.

Clinical Features

Cats

     • Variable disease severity – ranges from inapparent infection to marked depression and death.

     • Intermittent fever (50% of the time) during the acute phase.

     • Depression, weakness, anorexia, pale mucous membranes.

     • Splenomegaly.

     • Icterus - rare.

Dogs

     • Mild or inapparent signs – pale mucous membranes and listlessness.

     • In splenectomized dogs – signs more like cats.

Differential Diagnosis

     • Other causes of hemolytic anemia:- IMHA; babesiosis (not in cats in the U.S.); cytauxzoonosis (cats only); Heinz body hemolytic anemia; microangiopathic hemolytic anemia; pyruvate kinase deficiency; phosphofructokinase deficiency (dogs only).

     • Differentiated from IMHA – only by recognition of parasites in blood (stained blood film or PCR-based assays); both disorders may be Coombs test-positive.

     • Babesia and Cytauxzoon spp. – differ in morphology from these mycoplasmal organisms.

     • New methylene blue stains – used to identify Heinz bodies.

     • Enzyme assays or specialized DNA tests – used to diagnose pyruvate kinase and phosphofructokinase deficiencies.

Diagnostics

CBC

     • Anemia – usually with reticulocytosis if regenerative. Also anisocytosis, macrocytosis, Howell-Jolly bodies, and occasionally marked normoblastemia.

     • Anemia – may appear poorly regenerative if a precipitous decrease in PCV has occurred early in the disease or if there are other concurrent disorders (e.g., FeLV or FIV infections in cats).

     • Autoagglutination – may see in feline blood samples after they cool to below body temperature.

     • Variable total and differential leukocyte counts of little diagnostic assistance.

     • Hemoglobinemia – rarely observed, so no hemoglobinuria reported.

Biochemical profile

     • Hyperbilirubinemia – seen in some cases but seldom severe.

     • Substantial bilirubinuria – seen in some dogs.

     • Abnormalities related to anemic hypoxia or profile can be normal.

     • Hypoglycemia – possible in moribund cats (not specific to this disease).

     • Plasma protein concentrations – usually normal but may be increased.

     • Routine blood stains (e.g., Wright - Giemsa) to identify organisms in blood films; overall, low sensitivity; examine before treatment is begun as treatment increases false negatives.

     • Reticulocyte – stains can't be used as punctate reticulocytes (cats) appear similar to parasites.

     • Organisms must be differentiated from precipitated stain – refractile drying or fixation artifacts, poorly staining Howell-Jolly bodies, and basophilic stippling can confuse diagnosis.

     • Feline organisms – small blue-staining cocci, rings, or rods on RBCs.

     • Canine organisms – commonly form chains of organisms that appear as filamentous structures on the surface of RBCs.

     • Parasitemia – cyclic, and thus organisms not always identifiable in blood (especially in cats).

     • PCR-based assays (on whole blood or dry) – significantly more sensitive than cytology.

     • Direct Coombs test – may be positive.

Therapeutics

     • Without therapy – mortality with the larger form may reach 30% in cats.

     • Outpatient treatment – unless severely anemic or moribund.

     • Blood transfusions – required when the anemia is considered life-threatening.

     • IV administration of glucose-containing fluid – recommended in moribund animals.

Drugs of choice

     • Doxycycline (10mg/kg/day, PO, for 2 wks) – drugs of choice.

     • Enrofloxacin (5mg/kg/day, PO) – efficacious alternative to doxycycline.

     • Prednisolone – may be given to severely anemic animals (to treat immune mediated destruction of RBCs); gradually decrease dosage as the PCV increases.

Precautions/interactions

     • Tetracycline antibiotics – may produce fever or evidence of gastrointestinal disease in cats; use a lower dosage or a different drug, or discontinue drug therapy altogether.

     • Doxycycline – may cause esophagitis and stricture in cats; use liquid form or give with food.

     • Enrofloxacin – has been associated with blindness in cats; may cause arthropathy in young cats.

     • Chloramphenicol – may use in dogs; can cause dose-dependent erythroid hypoplasia in cats.

Comments

     • Examine animal after 1 week of treatment – to confirm that PCV has risen.

     • Alert owner – cat may remain carriers even after completion of treatment but seldom relapse with disease once PCV returns to normal.

     • Prognosis usually excellent in cats – if treated early in disease.

REFERENCES

1. Willi B, Boretti FS, Cattori V, et al: Identification, molecular characterization, and experimental transmission of a new hemoplasma isolate from a cat with hemolytic anemia in Switzerland. J Clin Microbiol 2005;43(6):2581-5.

2. Sykes JE, Drazenovich NL, Ball LM, et al: Use of conventional and real-time polymerase chain reaction to determine the epidemiology of hemoplasma infections in anemic and nonanemic cats. J Vet Intern Med 2007;21(4):685-93.

3. Tasker S, Peters IR, Papasouliotis K, et al. Description of outcomes of experimental infection with feline haemoplasmas: Copy numbers, haematology, Coombs' testing and blood glucose concentrations. Vet Microbiol 2009;139(3-4):323-332.

4. Sykes JE, Terry JC, Lindsay LL, et al: Prevalences of various hemoplasma species among cats in the United States with possible hemoplasmosis. J Am Vet Med Assoc 2008;232(3):372-9.

5. Jefferies R, Ryan UM, Jardine J, et al.Babesia gibsoni: Detection during experimental infections and after combined atovaquone and azithromycin therapy. Exp Parasitol 2007;117:115-23.

6. Irwin PJ. Canine babesiosis: from molecular taxonomy to control. Parasites & Vectors 2009;2 (S1):1-9.

Recent Videos
Richard Gerhold, DVM, MS, PhD, DACVM (Parasitology)
merck leptospirosis panel
merck leptospirosis panel
merck leptospirosis panel
dvm360 Live! with Dr. Adam Christman
Vet Perspective parasitology discussion
Vet Perspective parasitology discussion
© 2024 MJH Life Sciences

All rights reserved.